Hypomagnesemia and Hypocalcemia Association Following Thyroidectomy

Sponsor
King Saud University (Other)
Overall Status
Completed
CT.gov ID
NCT04351451
Collaborator
(none)
74
1
13
5.7

Study Details

Study Description

Brief Summary

Magnesium plays a role in the active transport of calcium (Ca+2) and potassium ions across cell membranes. Most of it is intracellular or in the bone , however less than 1% of magnesium is in the blood serum. Hypoparathyroidism post thyroidectomy leads to acute Hypocalcemia that leads to hypomagnesemia. The relation of Ca+2 and magnesium (Mg+2) metabolism is complex and mainly related to the interaction of these cations with parathyroid post thyroidectomy. (Mg+2) is an essential regulator of Ca+2 flux and intracellular action of Ca+2. Hypomagnesaemia impairs hypocalcaemia induced PTH release, which is corrected rapidly after magnesium replacement. Attempting to correct only hypocalcemia may prolong symptoms. It is important to monitor both Ca+2 & Mg+2 levels following thyroidectomy to facilitate prompt resolution of symptoms.

Aim of the study: is to highlight the prevalence of hypomagnesemia following thyroidectomy and its association with hypocalcemia which mandate early recognition and treatment to prevent prolongation of hypocalcemia and permanent hypoparathyroidism

Methods:

IRB obtained (E20-4615) informed consent taken from all patient. This is prospective open Label observational study in patients underwent thyroidectomy .the study period was from January 2019 to January 2020. Total of 74 patients with normal renal function. Corrected serum Ca+2, magnesium, phosphate level and vitamin D level are all checked pre operatively and in the first post-operative day.

Result:

Post thyroidectomy 56.8% of patients had hypomagnesemia. 59.5.1% patients had hypocalcemia and 41.9% of patients had low both Ca+2 and Mg+2 (P=0.004)

Conclusion:

Hypocalcemia and hypomagnesemia following thyroidectomy is of multi factorial related mainly to Ca+2, Mg+2 interaction.

Keywords: Hypomagnesemia. Hypocalcemia. Thyroidectomy

Condition or Disease Intervention/Treatment Phase
  • Procedure: thyroidectomy

Detailed Description

Methods:

A prospective study for 1 year starting 1/1/2019 to 1/1/2020. A total 74 patients with normal renal function .admitted for thyroidectomy. Preoperative serum calcium, magnesium, phosphate and vitamin D level all checked. Postoperatively corrected serum calcium, magnesium and phosphate level are checked. The serum calcium less than 2.12mmol/l is corrected with oral or IV calcium infusion plus vitamin D depending on the severity of symptoms. Any serum magnesium less than 0.75mmol/l is corrected with infusion magnesium sulfate. Calcium and magnesium level monitored and corrected according to the result.

Statistical analysis:

Statistical analysis was performed using statistical package for the social sciences (SPSS) version 23.0 software (SPSS Inc., Chicago ,IL,USA). If normal distributed, continuous variable were presented as mean (SD) Student t-test for paired observation was used for statistical. Pearson Chi-square test was used to compare the percentage for categorical variables. P less than 0.05 indicate statistically significant difference

Study Design

Study Type:
Observational
Actual Enrollment :
74 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Hypomagnesemia and Hypocalcemia Association Following Thyroidectomy
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Jan 1, 2020
Actual Study Completion Date :
Feb 1, 2020

Outcome Measures

Primary Outcome Measures

  1. hypomagnesemia post thyroidectomy [one year period]

    magnesium serum level less than 0.75 mmol/l

  2. Hypocalcemia post thyroidectomy [one year period]

    calcium serum level less than 2.12 mmol/l

Secondary Outcome Measures

  1. association of Hypomagnesemia and Hypocalcemia [one year period]

    calculate the percentage of association of both metabolic derangement post thyroidectomy

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

all patients admitted for thyroidectomy -

Exclusion Criteria:

patient with renal disease

-

Contacts and Locations

Locations

Site City State Country Postal Code
1 College of Medicine , King Saud University Riyadh Central Region Saudi Arabia 11352

Sponsors and Collaborators

  • King Saud University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amal Abdullah Abdulkareem, consultant&assistant professor, King Saud University
ClinicalTrials.gov Identifier:
NCT04351451
Other Study ID Numbers:
  • 42CFR Part11
First Posted:
Apr 17, 2020
Last Update Posted:
Apr 17, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Amal Abdullah Abdulkareem, consultant&assistant professor, King Saud University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 17, 2020